CNS Disorders  >>  Intuniv (guanfacine XR) 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Intuniv (guanfacine XR) / Shionogi, Takeda
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
NorAD, NCT03116126 / 2016-002598-36: Noradrenergic Add-on Therapy With Guanfacine

Active, not recruiting
3
148
Europe
Guanfacine, Placebo
Imperial College London
Alzheimer Disease
08/24
08/24
ADAPT, NCT02136147: ADHD Medication and Predictors of Treatment Outcome

Completed
N/A
632
Europe
methylphenidate medication, N06BA04, Concerta, Ritalin, Equasym, Medikinet, atomoxetine medication, N06BA09, Strattera, lisdexamphetamine medication, N06BA12, Elvanse, guanfacine medication, C02AC02, Intuniv
Karolinska Institutet
Attention Deficit Disorder With Hyperactivity (ADHD)
07/21
06/22
NCT05870605: Drug Use Study With Intuniv® in European Countries

Completed
N/A
5000
Europe
No Intervention
Shire
Attention Deficit Hyperactivity Disorder (ADHD)
04/22
04/22
AGUALIS, NCT03333668: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Active, not recruiting
N/A
20
Europe
Lisdexamfetamine dimesylate, Vyvanse (Shire Pharmaceuticals Ltd.), Guanfacine Extended Release Oral Tablet, Intuniv (Shire Pharmaceuticals Ltd.), Placebo
King's College London, Shire
ADHD
12/22
03/25

Download Options